Support teaching, research, and patient care.
Biological bases of depressive disorders;, glucocorticoid/dopamine interactions in delusional depression;, pharmacologic treatment of depressive disorders.
Opiate Suicide Study in Patients With Major Depression Recruiting
To explore whether intravenous ketamine followed by buprenorphine produces more rapid and sustained anti-suicidal effects than ketamine followed by placebo, investigators will conduct a single study that will take approximately 2.5 years to complete. 60 subjects (60 infusions) or approximately 24 infusions per year.
View full details
Clinical and Biological Characteristics of Psychotic Depression Not Recruiting
The primary objective of this study is to investigate the relationships among findings in structural and functional neuroimaging, cognitive testing and HPA (hypothalamic-pituitary-adrenal) axis dysregulation in psychotic depression.
Stanford is currently not accepting patients for this trial. For more information, please contact Lakshika Tennakoon, 650-723-3305.
Genetics of Symptomatology and Treatment Response in Psychotic Major Depression Not Recruiting
We hope to learn more about the biology of psychiatric illness with the hope of improving the diagnosis and treatment of such psychiatric conditions as major depression.
Stanford is currently not accepting patients for this trial. For more information, please contact Gregory H Cohen, MSW, 650-723-3305.
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors Not Recruiting
Intrapatient dose escalation study of desipramine in subjects with small cell lung cancer (SCLC) and other high-grade neuroendocrine tumors.
Stanford is currently not accepting patients for this trial. For more information, please contact CCTO, 650-498-7061.
Identifying Biological Markers for Severe Depression Not Recruiting
The primary objective of this study is to investigate the biological components of major depression. The investigators are particularity interested in genetic variation and how it contributes to cortisol (because cortisol is higher in severe depression than mild depression or healthy controls) and how it contributes to clinical symptoms, especially suicidal ideation/behavior and psychosis.
Stanford is currently not accepting patients for this trial. For more information, please contact Maureen H Chang, B.S., 650-725-4620.
A Brief Behavioral Sleep Intervention for Depression Among Military Veterans Not Recruiting
This study investigates the impact of brief behavioral insomnia treatment on depressive symptoms among military veterans.
Stanford is currently not accepting patients for this trial. For more information, please contact Nyree White, BA, 650-724-5368.
International Study to Predict Optimised Treatment - in Depression Not Recruiting
The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine, Sertraline) in patients diagnosed with major depressive disorder. This study is focused on outcomes which may impact on how "personalised medicine" is implemented in depression.
Stanford is currently not accepting patients for this trial. For more information, please contact Maureen Chang, 7254620.
